Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Consun Pharmaceutical Group Ltd. ( (HK:1681) ) has shared an update.
Consun Pharmaceutical Group Limited has declared a final ordinary cash dividend of HKD 0.4 per share for the financial year ended 31 December 2025, signaling confidence in its financial performance and cash generation. Subject to shareholder approval on 26 May 2026, the dividend will go ex-dividend on 9 June, with a record date of 10 June and payment scheduled for 22 June 2026, providing income visibility and returns to existing shareholders.
The company has set the latest time for shareholders to lodge transfer documents at 16:30 on 10 June 2026, ensuring proper entitlement to the declared dividend. The announcement, which includes no withholding tax arrangements or additional corporate actions, underscores a straightforward capital return to investors and reflects steady capital management practices by the board.
The most recent analyst rating on (HK:1681) stock is a Buy with a HK$19.50 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.
More about Consun Pharmaceutical Group Ltd.
Consun Pharmaceutical Group Limited is a Hong Kong-listed pharmaceutical company focused on developing and manufacturing healthcare products. The group operates in the broader pharmaceutical and healthcare sector, serving patients and medical institutions through its portfolio of drug and wellness offerings.
Average Trading Volume: 1,749,899
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.07B
For an in-depth examination of 1681 stock, go to TipRanks’ Overview page.